TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21607821

Group type: EXPERIMENTAL
Intervention: Extralight titanized polypropylene mesh (ELW group) TiMesh(®) 16 g/m(2) without any fixation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard heavyweight polypropylene mesh (HW group) Prolene 90 g/m(2) fixed with two absorbable sutures
Number of subjects: 300
Study: 18303984

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study: 16438762

Group type: EXPERIMENTAL
Intervention: Esomeprazole 3 x 40 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 12559678

Group type: EXPERIMENTAL
Intervention: valsartan (80 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) (25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 11436909

Group type: EXPERIMENTAL
Intervention: Narcotic analgesia administered in the emergency department (ED)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narcotic analgesia
Number of subjects: 0
Study: 9592510

Group type: EXPERIMENTAL
Intervention: Learning process-based tutorials
Number of subjects: 2

Group type: COMPARATOR
Intervention: Theory-based tutorials
Number of subjects: 2
Study: 7530026

Group type: EXPERIMENTAL
Intervention: Reactivity to gp41 epitopes (amino acids 571-585, 736-750, and perhaps 650-663)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reactivity to gp120 epitopes (amino acids 466-480 and 475-486) and one gp41 epitope (amino acids 547-576)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies to HIVLAI
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Testing of 102 HIV-1 Env peptides
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Reproducibility of results
Number of subjects: 65
Study: 2968102

Group type: EXPERIMENTAL
Intervention: Propanetetraphosphonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albumin colloid
Number of subjects: 0
Study: 31523249

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide mucoadhesive films
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mucoadhesive films
Number of subjects: 60
Study: 28943912

Group type: EXPERIMENTAL
Intervention: H2H nutrition management
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine nutrition management
Number of subjects: 86
Study: 26281947

Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered self-help intervention
Number of subjects: 69
Study: 23281973

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfusion when hemoglobin fell below 7 g/dL)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfusion when hemoglobin fell below 9 g/dL)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 921

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 921
Study: 20825901

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care (including furosemide, oxygen, and high-dose boluses of isosorbide dinitrate)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 124
Study: 19515413

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once a day
Number of subjects: 464

Group type: COMPARATOR
Intervention: Exenatide 10 microg twice a day
Number of subjects: 464
Study: 17090235

Group type: EXPERIMENTAL
Intervention: Online teaching module
Number of subjects: 48
Study: 15612859

Group type: EXPERIMENTAL
Intervention: High-dose nicotine (35 mg) patch
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 158
Study: 11282204

Group type: EXPERIMENTAL
Intervention: Meningococcal serogroup C conjugate vaccine (MenC)
Number of subjects: 322
Study: 9352695

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional transurethral resection of the prostate (TURP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both TUVP and TURP
Number of subjects: 70
Study: 8462384

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 3081923

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Yohimbine (30 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg) and Yohimbine (30 mg) together
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30027590

Group type: EXPERIMENTAL
Intervention: Baked milk in the form of muffin for 6 months followed by baked cheese in the form of pizza for another 6 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group instructed to strictly avoid any milk products for 1 year
Number of subjects: 84
Study: 28028958

Group type: EXPERIMENTAL
Intervention: Exergames (EG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 25216572

Group type: EXPERIMENTAL
Intervention: Atlas-based autosegmentation (AS + R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual segmentation (MS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atlas-based autosegmentation (AS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attending approved OARs
Number of subjects: 40
Study: 23090523

Group type: EXPERIMENTAL
Intervention: Hydrocodone-acetaminophen (10 mg hydrocodone and 650 mg acetaminophen)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydrocodone-acetaminophen
Number of subjects: 120
Study: 20406432

Group type: EXPERIMENTAL
Intervention: High-phenol virgin olive oil (398 ppm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-phenol virgin olive oil (70 ppm)
Number of subjects: 20
Study: 17669242

Group type: EXPERIMENTAL
Intervention: Serum argininosuccinate lyase (ASL)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (AST)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Serum ASL levels in liver cancer, acute hepatitis, liver cirrhosis, chronic hepatitis
Number of subjects: 291
Study: 16124155

Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided and double-injection (ND) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided and double-injection (UD) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided and single-injection (US) group
Number of subjects: 90
Study: 11936548

Group type: EXPERIMENTAL
Intervention: Protective equipment during functional analysis
Number of subjects: 2
Study: 10519465

Group type: EXPERIMENTAL
Intervention: Tailored weight-loss materials
Number of subjects: 198

Group type: COMPARATOR
Intervention: AHA brochure
Number of subjects: 198

Group type: COMPARATOR
Intervention: AHA-content formatted to look like tailored materials
Number of subjects: 198
Study: 8619007

Group type: EXPERIMENTAL
Intervention: DN-2327 (3 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.8 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DN-2327 (2 mg)
Number of subjects: 12
Study: 2057271

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Non-hypnotic distraction/relaxation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Attention placebo (control)
Number of subjects: 54
Study: 6611720

Group type: EXPERIMENTAL
Intervention: Graded exercises with the perineometer exerciser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional exercises without the perineometer exerciser
Number of subjects: 22
Study: 31502498

Group type: COMPARATOR
Intervention: Placebo arm of a previously-completed prospective clinical trial
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Patients in MCS
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Patients with preserved language function (MCS+)
Number of subjects: 95
Study: 29791829

Group type: EXPERIMENTAL
Intervention: Burosumab every 2 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Burosumab every 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 27161018

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase (0.6 mg/kg)
Number of subjects: 3310

Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase (0.9 mg/kg)
Number of subjects: 3310
Study: 24624911

Group type: EXPERIMENTAL
Intervention: SNPs in the thiopurine pathway genes ABCC4, ABCC5, IMPDH1, ITPA, SLC28A3 and XDH
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Functional validation studies by siRNA knockdown in cancer cell lines
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: SNPs located within or near ATP6AP2, FRMD4B, GNG2, KCNMA1 and NME1
Number of subjects: 589
Study: 23394510

Group type: EXPERIMENTAL
Intervention: Routine ED treatment including oral prednisone at 60 mg and inhalation of nebulized albuterol and ipratropium
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Initial eNO levels
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Change in pre‐ versus posttreatment eNO (ΔeNO)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Initial PEF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ΔPEF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ED visit duration
Number of subjects: 28
Study: 20029212

Group type: EXPERIMENTAL
Intervention: Home Visits (HV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (HV favored)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (CT favored)
Number of subjects: 0
Study: 18757663

Group type: EXPERIMENTAL
Intervention: HSIL cytology with HPV16-positive, low-grade or worse colposcopic impression, HSIL or equivocal HSIL cytology
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HSIL cytology with HPV16-negative, less than low-grade colposcopic impression, not called HSIL or equivocal HSIL
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HSIL cytology (general population)
Number of subjects: 411
Study: 15973602

Group type: EXPERIMENTAL
Intervention: Patients with 70% stenosis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with 80% stenosis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with 90% stenosis
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with stenoses > 95%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 62
Study: 12748465

Group type: EXPERIMENTAL
Intervention: 1% lidocaine injection
Number of subjects: 56
Study: 10480222

Group type: EXPERIMENTAL
Intervention: Oral protein supplement (7.8 g/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9124982

Group type: EXPERIMENTAL
Intervention: Cefpirome treatment for wound infections
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cefpirome treatment for burn infections
Number of subjects: 25
Study: 1832209

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (20 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 95
Study: 7080890

Group type: EXPERIMENTAL
Intervention: Urine acidification in nonsmoking females after smoking one cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urine alkalinization in nonsmoking females after smoking one cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Males (no specific intervention mentioned)
Number of subjects: 0
Study: 31882030

Group type: EXPERIMENTAL
Intervention: Tricalcium silicate (Biodentine)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 58
Study: 28887154

Group type: EXPERIMENTAL
Intervention: Eccentric only (ERE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eccentrically biased resistance exercise (EBRE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Traditional resistance exercise (TRE)
Number of subjects: 33
Study: 25891010

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 23857436

Group type: EXPERIMENTAL
Intervention: Combined general and epidural anesthesia (group GE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General anesthesia (group G)
Number of subjects: 54
Study: 21360470

Group type: EXPERIMENTAL
Intervention: 4-hour bicarbonate hemodialysis
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 8-hour bicarbonate hemodialysis
Number of subjects: 11
Study: 19411801

Group type: EXPERIMENTAL
Intervention: Web-based education program on blood-borne infection control
Number of subjects: 0
Study: 17515172

Group type: EXPERIMENTAL
Intervention: Resting theta activity in the rostral anterior cingulate cortex (ACC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resting theta activity in the rostral ACC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole brain voxelwise approach
Number of subjects: 20
Study: 15346745

Group type: EXPERIMENTAL
Intervention: Allograft in an experimental putty carrier plus a calcium sulfate barrier (PUT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bovine-derived xenograft (BDX) plus a collagen membrane
Number of subjects: 24
Study: 11842065

Group type: EXPERIMENTAL
Intervention: 3.5 g/kg of [(13)C]glucose (approximately 2 g/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9818846

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gabapentin 1,800 mg/day
Number of subjects: 218

Group type: COMPARATOR
Intervention: Carbamazepine 600 mg/day
Number of subjects: 218
Study: 7981446

Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 471

Group type: COMPARATOR
Intervention: Non-users of oral contraceptives
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Long-term OC users (4 years or longer)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: OC users with tumors > 2 cm
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: OC users with axillary node-positive tumors (1-3 nodes)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: OC users with axillary node-positive tumors (≥ 4 nodes)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: OC users with low estrogen receptor content
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: OC users with low progesterone receptor content
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: OC users with poorly differentiated tumors
Number of subjects: 471
Study: 2024986

Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7032839

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study: 31426673

Group type: EXPERIMENTAL
Intervention: Elacestrant (RAD1901)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care endocrine monotherapy treatment (fulvestrant or an aromatase inhibitor, per investigator's choice)
Number of subjects: 0
Study: 27637736

Group type: EXPERIMENTAL
Intervention: Functional star-shape taping for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham functional taping for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Minimal intervention, one session
Number of subjects: 120
Study: 26495909

Group type: EXPERIMENTAL
Intervention: Extreme distress class
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: High depressive and anxiety symptom class
Number of subjects: 232

Group type: COMPARATOR
Intervention: Low distress class
Number of subjects: 232

Group type: COMPARATOR
Intervention: Moderate distress class
Number of subjects: 232

Group type: COMPARATOR
Intervention: High NICU-related distress class
Number of subjects: 232
Study: 24424076

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 52
Study: 22964434

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation ON
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deep brain stimulation OFF
Number of subjects: 0
Study: 19764666

Group type: EXPERIMENTAL
Intervention: Single layer closure (closure of skin and subcutaneous tissues together)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Two layer closure (closure of skin and subcutaneous tissues separately)
Number of subjects: 160
Study: 17327251

Group type: EXPERIMENTAL
Intervention: Light anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Five different conditions of anaesthesia (intubation, skin incision, deep anaesthesia, moderate anaesthesia, light anaesthesia)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Second test point
Number of subjects: 40
Study: 15076648

Group type: EXPERIMENTAL
Intervention: Urban dust exposure at 500 microg/m3 for 3 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control air exposure
Number of subjects: 30
Study: 11425688

Group type: EXPERIMENTAL
Intervention: High oxygen-transmissible soft lenses
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Hyper oxygen-transmissible soft lenses
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Hyper oxygen-transmissible RGP lenses
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable lenses
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: All test lenses
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 246
Study: 9532327

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g every 8 hours for 3-14 days, average 9 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ceftazidime (1 g every 8 hours) and Amikacin (0.5 g every 12 hours for 2-14 days, average 9 days)
Number of subjects: 95
Study: 7526728

Group type: EXPERIMENTAL
Intervention: Regional anaesthetic technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 72
Study: 2644339

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine (control)
Number of subjects: 0
Study: 339322

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentagastrin and somatostatin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 31707500

Group type: EXPERIMENTAL
Intervention: Daily symptom screening using the SPARK platform
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 30
Study: 31023034

Group type: EXPERIMENTAL
Intervention: ECG gating during computed tomography (CT) acquisition
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-ECG gating during computed tomography (CT) acquisition
Number of subjects: 62
Study: 28954640

Group type: EXPERIMENTAL
Intervention: β2‐1 fructan (3×5 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maltodextrin (3×5 g/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: β2‐1 fructan
Number of subjects: 30
Study: 25517389

Group type: EXPERIMENTAL
Intervention: Continuous exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interval exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control ABPM (no exercise)
Number of subjects: 20
Study: 23804157

Group type: EXPERIMENTAL
Intervention: Cement directed kyphoplasty system (CDKS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cement directed kyphoplasty system (CDKS) and Vertebroplasty
Number of subjects: 77
Study: 20945252

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention to increase fruit and vegetable intake by two extra portions daily over 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition performing an equivalent neutral task
Number of subjects: 0
Study: 19738372

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 23247

Group type: EXPERIMENTAL
Intervention: Double-blind design
Number of subjects: 23247

Group type: EXPERIMENTAL
Intervention: Short maximum allowed delay from symptom onset to randomization
Number of subjects: 23247

Group type: EXPERIMENTAL
Intervention: Time effect
Number of subjects: 23247
Study: 17083637

Group type: EXPERIMENTAL
Intervention: SLIPA (Streamlined Liner of the Pharynx Airway)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SS-LM (Soft Seal Laryngeal Mask)
Number of subjects: 36
Study: 14697435

Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11386392

Group type: EXPERIMENTAL
Intervention: Therapy plus imagery (10-minute guided imagery sessions after each therapy session, plus home practice twice weekly)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Therapy only (control group)
Number of subjects: 13
Study: 9404369

Group type: EXPERIMENTAL
Intervention: R-salbutamol 1.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Racemic salbutamol 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-salbutamol 1.25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8489327

Group type: EXPERIMENTAL
Intervention: Liothyronine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3687684

Group type: EXPERIMENTAL
Intervention: Supine exercise
Number of subjects: 63

Group type: COMPARATOR
Intervention: Upright exercise
Number of subjects: 63